US Patent

US8470361 — Non-abusable pharmaceutical composition comprising opioids

Method of Use · Assigned to Orexo AB · Expires 2030-05-22 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition that combines an opioid analgesic with an opioid antagonist in a specific particulate form to prevent opioid abuse.

USPTO Abstract

There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1425 — Subutex
U-1425 — Subutex
U-1425 — Subutex
U-1425 — Subutex
U-1425 — Subutex
U-1425 — Subutex

Patent Metadata

Patent number
US8470361
Jurisdiction
US
Classification
Method of Use
Expires
2030-05-22
Drug substance claim
No
Drug product claim
Yes
Assignee
Orexo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.